Shopping Cart
- Remove All
- Your shopping cart is currently empty
Dostarlimab (TSR-042) is a programmed cell death protein 1 (PD-1) receptor immune checkpoint inhibitor that blocks interactions with PD-L1 and PD-L2, used in the study of endometrial cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $263 | In Stock | |
5 mg | $689 | In Stock | |
10 mg | $1,080 | In Stock | |
25 mg | $1,630 | In Stock | |
50 mg | $2,180 | In Stock |
Description | Dostarlimab (TSR-042) is a programmed cell death protein 1 (PD-1) receptor immune checkpoint inhibitor that blocks interactions with PD-L1 and PD-L2, used in the study of endometrial cancer. |
Targets&IC50 | PD-1 (human):2.0 nM (EC50) |
In vitro | Dostarlimab has a strong binding affinity with human and cynomolateral monkey PD-1 protein with Kd of 0.3 and 0.5 nM, respectively. Dostarlimab binds to PD-1 on the surface of recombinant human and cynomophobe monkey cells expressed on CHO-K1 cells with EC50 values of 2.0 and 3.4 nM, respectively. Dostarlimab effectively blocked PD-1/PD-L1 and PD-1/PD-L2 binding with IC50 values of 1.8 and 1.5 nM, respectively. Adding Dostarlimab to the SEB-stimulated PBMC resulted in increased IL-2 production with an EC50 of about 0.1 nM, suggesting that Dostarlimab induced T cell activation. [1] |
In vivo | Dostarlimab(200μg/ pill twice weekly) inhibited tumor growth in the MDA-MB-436 breast cancer model. [1] |
Alias | TSR-042, TSR042, GSK-4057190A, GSK4057190A, ANB011, ANB 011 |
Cas No. | 2022215-59-2 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.